We provide you with 20 years of free, institutional-grade data for AIM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AIM. Explore the full financial landscape of AIM stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about AIM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
AIM ImmunoTech Inc(NYSE MKT:AIM) 
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for t...
Website: http://www.hemispherx.net
Founded: 1966
Full Time Employees: 24
CEO: Thomas Kenwood Equels
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends